Home Nav
Nextech Invest Logo

news

News

14.06.2019

Kura Oncology

Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma

14.06.2019

Blueprint Medicines

Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

04.06.2019

Arvinas

Arvinas and Bayer to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications

03.06.2019

Blueprint Medicines'

Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019

29.05.2019

Arvinas

Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer

22.05.2019

Ideaya Biosciences

Ideaya Biosciences Announces Pricing of Initial Public Offering

21.05.2019

Merck & Co.

Merck & Co. to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline

16.05.2019

Blueprint Medicines

Blueprint Medicines Announces Data Presentations at ASCO and EHA Meetings from Registration-Enabling Clinical Trials of Avapritinib and BLU-667 Across Multiple Patient Populations

09.05.2019

Peloton Therapeutics

Peloton Therapeutics Announces Completion of Enrollment in Phase 2 Trial of PT2977 for Treatment of von Hippel-Lindau Disease-associated Renal Cell Carcinoma

08.05.2019

Ideaya Biosciences

Ideaya Biosciences Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions

07.05.2019

Peloton Therapeutics

Peloton Therapeutics Appoints Timothy P. Coughlin and Thilo Schroeder, Ph.D. to its Board of Directors

30.04.2019

Vividion Therapeutics

Vividion Therapeutics Announces Oversubscribed $82Million Series B Financing

18.04.2019

Arrakis Therapeutics

Arrakis Therapeutics Announces $75 Million Series B Financing To Advance a New Class of Small-Molecule Medicines Targeting RNA

08.04.2019

Neon Therapeutics

Neon Therapeutics Announces Completion of Enrollment in Phase 1b NT-002 Clinical Trial of NEO-PV-01 in Metastatic Non-Small Cell Lung Cancer

02.04.2019

Kura Oncology

Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications

02.04.2019

Arvinas

Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer

01.04.2019

Turning Points Therapeutics'

Turning Points Therapeutics' Kinase Inhibitors Show High Potency against Targeted Oncogene Drivers and Their Mutations

01.04.2019

Peloton Therapeutics

Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium

31.03.2019

Neon Therapeutics

Neon Therapeutics Presents Updated Data from Ongoing Phase 1b NT-001 Clinical Trial of Personal Neoantigen Vaccine NEO-PV-01 at AACR 2019 Annual Meeting

25.03.2019

Turning Points Therapeutics

Turning Points Therapeutics Appoints Jim Mazzola to Lead Corporate Communication and Investor Relations

Newsletter

Keep me updated about investment opportunities in the area of oncology and life sciences.

Register


Latest Newsletters

June 2019June 2019June 2018April 2018

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close

This website uses cookies to provide you with the best possible service. By using our website, you consent to the use of cookies in accordance with our privacy policy. Here you can find out more.